CytoDyn Inc. (CYDY)
OQB · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About CytoDyn Inc.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Quarterly Financials
| Metric | 2025-02-28 | 2025-05-31 | 2025-11-30 | 2026-02-28 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.0M | -5.1M | -5.1M | -6.3M |
| Net Income | -4.8M | -6.0M | -22.6M | -4.7M |
| Diluted EPS | $0.00 | $nan | $-0.02 | $0.00 |
Annual Financials
| Metric | 2022-05-31 | 2023-05-31 | 2024-05-31 | 2025-05-31 |
|---|---|---|---|---|
| Revenue | 266K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 213K | -20.6M | 0.00 | |
| Operating Income | -145.4M | -40.6M | -18.1M | 9.7M |
| Net Income | -210.8M | -79.8M | -49.8M | 3.7M |
| Diluted EPS | $-0.31 | $-0.10 | $-0.05 | $0.00 |